AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Exclusion Criteria

• •1. Is currently participating in a study of an investigational agent or using an investigational device
• •2. Has an active autoimmune disease that has required systemic treatment in the past 2 years
• •3. Has an active infection requiring systemic therapy
• •4. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected)
• •5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
• •6. Has received a live virus vaccine within 30 days prior to first dose of study treatment
• •7. Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.